|
All patients
|
n=217
|
n=214
|
n=431
| |
|
missing data**
|
15
|
13
|
28
| |
|
number of patients evaluable
|
202
|
201
|
403
| |
|
Quantitative
| | | |
0.84*
|
|
Median nausea Score (Min-Max)
|
6.02 (1.11 – 7)
|
6.07 (1.22 – 7)
|
6.02 (1.11 – 7)
|
|
Mean ± sd
|
5.43 ± 1.57
|
5.45 ± 1.57
|
5.44 ± 1.57
|
|
Qualitative
| | | | |
|
Patients with no impact of nausea on daily life (i.e. a median score > 6), n (%)
|
103 (51.0)
|
102 (50.7)
|
205 (50.9)
|
0.96†
|
|
Stratum FAC-FEC
|
n=135
|
n=131
|
n=266
| |
|
missing data **
|
9
|
7
|
16
| |
|
number of patients evaluable
|
126
|
124
|
250
|
|
Quantitative
| | | | |
|
Median nausea score (min-max)
|
5.93 (1.11–7)
|
6.08 (1.65–7)
|
6.03 (1.11–7)
|
0.69*
|
|
Mean ± sd
|
5.37 (1.66)
|
5.48 (1.52)
|
5.42 (1.49)
| |
|
Qualitative
| | | | |
|
Patients with no impact of nausea on daily life (i.e. mean score > 6), n (%)
|
63 (50.0)
|
63 (50.8)
|
126 (50.4)
|
0.90†
|
|
Stratum TAC
|
n=82
|
n=83
|
n=165
| |
|
missing data**
|
6
|
6
|
12
| |
|
number of patients evaluable
|
76
|
77
|
153
| |
|
Quantitative
| | | | |
|
Median nausea score (min-max)
| |
6.07 (1.90-7)
| |
6.02 (1.22-7)
|
|
Mean ± sd
|
5.54 (1.43)
|
5.39 (1.66)
|
5.47 (1.55)
|
|
Qualitative
| | | | |
|
Patients with no impact of nausea on daily life (i.e. mean score > 6), n (%)
|
40 (52.6)
|
39 (50.6)
|
79 (51.6)
|
0.81†
|
|
Patients with susceptibility to NV (Yes)
|
n=61
|
n=66
|
n=127
| |
|
missing data**
|
2
|
4
|
6
|
|
number of patients evaluable
|
59
|
62
|
121
|
|
Quantitative
| | | |
|
Median nausea score (min-max)
|
5.85 (1.11–7)
|
5.81 (1.22–7)
|
5.83 (1.11–7)
|
0.36*
|
|
Mean ± sd
|
5.29 (1.66)
|
5.04 (1.71)
|
5.16 (1.69)
|
|
Qualitative
| | | | |
|
Patients with no impact of nausea on daily life (i.e. mean score > 6), n (%)
|
30 (49.2)
|
28 (42.4)
|
58 (45.7)
|
0.45†
|
